The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase
| Autor: | Nancy Joseph-Ridge, Michael J. Kukulka, Jing-Tao Wu, Reza Khosravan, Laurent Vernillet |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Xanthine Oxidase medicine.medical_specialty Adolescent Urinary system Urology Administration Oral Pharmacology Xanthine Gout Suppressants Young Adult chemistry.chemical_compound Febuxostat Sex Factors Pharmacokinetics medicine Humans Pharmacology (medical) Hyperuricemia Enzyme Inhibitors Xanthine oxidase Biotransformation Aged Hypoxanthine business.industry Age Factors medicine.disease Uric Acid Gout Thiazoles chemistry Pharmacodynamics Uric acid Female business Protein Binding medicine.drug |
| Zdroj: | The Journal of Clinical Pharmacology. 48:1014-1024 |
| ISSN: | 0091-2700 |
| DOI: | 10.1177/0091270008322035 |
| Popis: | Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase, which is currently being developed for the management of hyperuricemia in patients with gout. The effect of age and gender on the pharmacokinetics, pharmacodynamics, and safety of once-daily oral febuxostat 80 mg was assessed in healthy male and female subjects after 7 days. Following multiple dosing with febuxostat, there were no statistically significant differences in the plasma or urinary pharmacokinetic or pharmacodynamic parameters between subjects aged 18 to 40 years and >or=65 years. Although unbound peak concentration (C(max,u)) and area under the concentration-time curve (AUC(24,u)) for febuxostat were higher in women as compared with men (31.5 vs 23.6 ng/mL, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text